Reviewing Innovus Pharmaceuticals (OTCMKTS:INNVD) & Avenue Therapeutics (NASDAQ:ATXI)

Earnings & Valuation

This table compares Innovus Pharmaceuticals and Avenue Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovus Pharmaceuticals	$23.99 million	0.00	-$8.28 million	($4.16)	N/A
Avenue Therapeutics	N/A	N/A	-$10.38 million	($0.94)	-0.65

Innovus Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Innovus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Innovus Pharmaceuticals has a beta of 2.89, indicating that its share price is 189% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.92, indicating that its share price is 192% less volatile than the S&P 500.

Profitability

This table compares Innovus Pharmaceuticals and Avenue Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innovus Pharmaceuticals	-34.51%	-682.54%	-78.57%
Avenue Therapeutics	N/A	-471.57%	-296.50%

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

About Avenue Therapeutics

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.